Samuel Chen's firm, which controls Taiwan's Polaris Group, is the second-largest shareholder of Regencell Bioscience, while the SEC considers new rules for foreign issuers.

The entities involved

• Samuel Chen →

  researcher

  Nothing else this week.

• Regencell Bioscience →

  traditional Chinese herbal treatment company

  • Regencell Bioscience Holdings Limited began trading on the electronic stock exchange on June 1, 2026, while facing a lawsuit invoking federal securities laws.Sun 23:01
  • Diageo is offering American-Made Foreign Liquor whiskies, RBB Bancorp serves Asian-American communities, and Regencell operates a Traditional Chinese medicine company.Sun 17:22
• SEC →

  Slovak company

  • DHS, DOJ, and SEC formed a joint initiative to establish a Trade Fraud Task Force, setting standards for compliance.Mon 17:57
  • The Fidelis Partnership is incorporating in Bermuda and filing for an initial public offering on the NYSE, with principal offices in London and a main office in Dublin.Mon 17:12